证据与实践：硫酸镁的故事。

Evidence and practice: the magnesium sulphate story.

作者信息

Duley Lelia

机构信息

Resource Centre for Randomised Trials, Institute of Health Sciences, Old Road, Oxford OX3 7LF, UK.

出版信息

Best Pract Res Clin Obstet Gynaecol. 2005 Feb;19(1):57-74. doi: 10.1016/j.bpobgyn.2004.10.010.

DOI:10.1016/j.bpobgyn.2004.10.010

PMID:15749066

Abstract

There is now strong evidence from systematic reviews of randomised trials to support the use of magnesium sulphate for the prevention and treatment of eclampsia. Magnesium sulphate more than halves the risk of eclampsia for women with pre-eclampsia (relative risk (RR) 0.41, 95% confidence interval (CI) 0.29-0.58; number needed to treat (NNT) 102 (95% CI 72-173) compared to placebo. For treatment of eclampsia, magnesium sulphate lowers the risk of maternal death (RR 0.59, 95% CI 0.37-0.94) and of recurrence of further fits (RR 0.44, 95% CI 0.34-0.57) compared to diazepam. Magnesium sulphate also reduces the risk of further fits compared to phenytoin (RR 0.31, 95% CI 0.20-0.47) and to lytic cocktail (RR 0.09, 95% CI 0.03-0.24).

摘要

目前，来自随机试验系统评价的有力证据支持使用硫酸镁预防和治疗子痫。与安慰剂相比，硫酸镁可使先兆子痫女性发生子痫的风险减半以上（相对风险（RR）0.41，95%置信区间（CI）0.29 - 0.58；需治疗人数（NNT）102（95%CI 72 - 173））。对于子痫的治疗，与地西泮相比，硫酸镁可降低孕产妇死亡风险（RR 0.59，95%CI 0.37 - 0.94）以及再次抽搐发作的风险（RR 0.44，95%CI 0.34 - 0.57）。与苯妥英钠相比，硫酸镁还可降低再次抽搐发作的风险（RR 0.31，95%CI 0.20 - 0.47），与溶媒混合剂相比也是如此（RR 0.09，95%CI 0.03 - 0.24）。